Compare Dover Corp (DOV) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Inovio Pharmaceuticals Inc — how do they compare? Dover Corp trades at $188.83 (market cap $25.45B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: Dover Corp is far larger — about 226.8× Inovio Pharmaceuticals Inc's market cap, and Dover Corp pays a 1.11% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 73 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| DOV | INO | |
|---|---|---|
Market Cap | $25.45B | $112.19M |
Volume | 661,758 | 3,201,278 |
Sector | Industrials | Health |
52-Week High | $233.31 | $2.60 |
52-Week Low | $161.16 | $0.66 |
Typical Hold Time | 73 Days | 43 Days |
Enterprise Value | $26.95B | $83.51M |
Dividend Yield | 1.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $188.96, up 0.36% today, with a bearish technical signal from moving averages but neutral oscillators. The company maintains solid fundamentals, with a P/E of 22.85 and net income margin of 13.48%, while consistently beating EPS estimates in recent quarters. Recent news highlights product launches and strategic acquisitions, such as the completion of Cloeren's purchase, reinforcing growth initiatives.
The outlook is positive, supported by a strong analyst consensus with a $243.20 price target and no sell ratings. Risks include market volatility and execution of acquisition integration, but robust cash flow and dividend history provide stability. Upside potential hinges on continued earnings outperformance and sector tailwinds.
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
